Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

3 Months Ended

Nov. 30, 2023

	Carrying		Fair Value Measurement Using
	Value		Level 1		Level 2		Level 3		Total
Marketable Securities	$	72,427	$	72,427	$	-	$	-	$	72,427

	Carrying		Fair Value Measurement Using
	Value		Level 1		Level 2		Level 3		Total
Marketable Securities	$	125,642	$	125,642	$	-	$	-	$	125,642